A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Shao, Di ^a,b,c   Lin, Yongping ^d   Liu, Jilong ^a   Wan, Liang ^a   Liu, Zu ^a   Cheng, Shaomin ^a   Fei, Lingna ^a   Deng, Rongqing ^a   Wang, Jian ^a   Chen, Xi ^a   Liu, Liping ^d   Gu, Xia ^d   Liang, Wenhua ^d   He, Ping ^d   Wang, Jun ^b   Ye, Mingzhi ^a,b,c   He, Jianxing ^d  

^a BGI SHENZHEN   (China)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BGI Guangzhou   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; EVALUATION STUDY; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; REPRODUCIBILITY OF RESULTS;

EID: 84960171648     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22338     Document Type: Article

References (24)

1. Chen, W., Zheng, R., Zeng, H. & Zhang, S. Epidemiology of lung cancer in China. Thorac Cancer 6, 209-215 (2015).
2. Dienstmann, R., Rodon, J., Barretina, J. & Tabernero, J. Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. J Clin Oncol 31, 1874-1884 (2013).
3. Aisner, D. & Marshall, C. Molecular Pathology of Non-Small Cell Lung Cancer. Am J Clin Pathol 138, 332-346 (2012).
4. Maemondo, M. et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 362, 2380-2388 (2010).
5. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12, 735-742 (2011).
6. Solomon, B. et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N Engl J Med 371, 2167-2177 (2014).
7. Oxnard, G., Binder, A. & Janne, P. New Targetable Oncogenes in Non-Small-Cell Lung Cancer. J Clin Oncol 31, 1097-1104 (2013).
8. Pao, W. New Approaches to Targeted Therapy in Lung Cancer. Proc Am Thorac Soc 9, 72-73 (2012).
9. Li, T., Kung, H., Mack, P. & Gandara, D. Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies. J Clin Oncol 31, 1039-1049 (2013).
10. Kris, M. et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA 311, 1998 (2014).
11. Cardarella, S. et al. The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer. J Thorac Oncol 7, 1767-1774 (2012).
12. Shames, D. & Wistuba, I. The evolving genomic classification of lung cancer. J. Pathol. 232, 121-133 (2014).
13. Roychowdhury, S. et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Sci Transl Med 3, 111ra121-111ra121 (2011).
14. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11, 685-696 (2010).
15. Wagle, N. et al. High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing. Cancer Discov 2, 82-93 (2012).
16. Mamanova, L. et al. Target-enrichment strategies for next-generation sequencing. Nat Methods 7, 479-479 (2010).
17. Altmuller, J., Budde, B. & Nurnberg, P. Enrichment of target sequences for next-generation sequencing applications in research and diagnostics. Biol Chem 395 (2014).
18. Choi, M. et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci 106, 19096-19101 (2009).
19. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2, 146-158 (2010).
20. Kerick, M. et al. Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 4, 68 (2011).
21. Frampton, G. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31, 1023-1031 (2013).
22. Xuan, J., Yu, Y., Qing, T., Guo, L. & Shi, L. Next-generation sequencing in the clinic: Promises and challenges. Cancer Lett 340, 284-295 (2013).
23. Pritchard, C. et al. Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. J Mol Diagn 16, 56-67 (2014).
24. Wang, J. et al. The diploid genome sequence of an Asian individual. Nature 456, 60-65 (2008).